Radical Numerics Launches Omnii-1 Biology Model
Radical Numerics announced in a press release the launch of Omnii-1, a genome language model that learns from DNA, RNA, proteins and other molecular data. The company says researchers used the model to design a bacteriophage that was administered to a patient with a drug resistant bacterial infection.
The researchers designed phages targeting the patient's infection within weeks. A cocktail containing one of the AI designed phages killed the patient's bacterial isolate in laboratory testing before a physician administered it through compassionate use access.
Omnii-1 converts 28 types of biological data, including epigenetic signals, into a common representation. Radical Numerics is demonstrating the model across eight applications, including cancer vaccine design, analysis of genetic causes for rare diseases and biological threat detection.
The company says Omnii-1 identified AI-generated pathogen sequences that conventional screening tools missed during testing. Radical Numerics is also collaborating with Lawrence Livermore National Laboratory on biological threat detection.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 20 Georgia Tech instructions reduce chatbot agreement with delusions by 74% Oct 20 Gates Foundation Updates AI Principles on Access and Safety Oct 20 MEDITECH and Lifemed AI Partner on Claims Automation Oct 20 OpenAI acquires Orchestra Bio to bring AI agents into drug development Oct 20 Sophont launches Holon-S1 to predict gene activity from pathology slidesLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Illumina Launches BioInsight Platform for Genomic Research
Ultima Genomics Platform Selected for Precure's One Million Sample Dataset
Ultima Genomics to Sequence 80,000 Samples for UK Biobank Immune Study
Sophont launches Holon-S1 to predict gene activity from pathology slides
OpenAI acquires Orchestra Bio to bring AI agents into drug development
Daily AI Brief: the AI news that matters, in your inbox.